Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≤ 65 years

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 525-533

  Manoff, Susan B ^a   Liss, Charles ^a   Caulfield, Michael J ^a   Marchese, Rocio D ^a   Silber, Jeffrey ^a   Boslego, John ^a,c,d   Romero Steiner, Sandra ^b   Rajam, Gowrisankar ^b   Glass, Nina E ^b,c   Whitney, Cynthia G ^b   Carlone, George M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c PATH   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION; SEROTYPE; VACCINATION;

EID: 75749140099     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651131     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2007. http://www.cdc.gov/nddod/dbmd/abcs/survreports/spneu07.pdf.
2. 2.SimsRV,SteinmannWC,McConvilleJH,KingLR,ZwickWC,SchwartzJS. Theclinicaleffectivenessofpneumococcalvaccineintheelderly.AnnInternMed1988;108: 653-657.(Pubitemid18110935)
3. Butler FC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-1831.
4. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-1460.
5. 5. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755. (Pubitemid 36514705)
6. Spindler C, Hedlund J, Jasir A, Normark BH, Örtqvist Å. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008; 26:5541-5546.
7. Moberley SA, Holden J, Tathan DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008:CD000422.
8. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with communityacquired pneumonia. Clin Infect Dis 2006;42:1093-1101.
9. 9. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-1943. (Pubitemid 47606632)
10. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-1924.
11. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8): 1-24.
12. 12. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-248. (Pubitemid 29058113)
13. 13. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103. (Pubitemid 37357156)
14. Musher DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults. J Infect Dis 2010;201:516-524 (in this issue).
15. 15. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-121. (Pubitemid 30067069)
16. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4:415-422.
17. 17. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514-519. (Pubitemid 36890430)
18. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8: 266-272.
19. 19. Marchese RD, Jain NT, Antonello J, et al. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assay. Clin Vaccine Immunol 2006; 13:905-912. (Pubitemid 44409630)
20. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981.
21. 21.CasadevallA,ScharffMD.Serumtherapyrevisited: animalmodelsofinfectionanddevelopmentofpassiveantibodytherapy. AntimicrobAgentsChemother1994;38:1695-1702.(Pubitemid24250712)
22. Cecil RL,. Effects of very early serum treatment in pneumococcus type 1 pneumonia. JAMA 1937; 108:689-692.
23. Musher DM, Phan HM, Watson DA, Baughn RE. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J Infect Dis 2000; 182:158-167.
24. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281-288.
25. Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991;9:403-407.
26. 26. Davidson MD, Bulkow LR, Grabman J, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994;154:2209-2214. (Pubitemid 24317268)
27. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993; 17:66-73.
28. 28. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16:308-318. (Pubitemid 36519814)
29. Hilleman MR, Carlson AJ Jr, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981;3(Suppl):S31-S42.
30. Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 1983; 173:270-275.
31. Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci 1987;293:279-284.
32. Sutliff W, Finland M. Antipneumococcic immunity reactions in individuals of different ages. J Exp Med 1932;55:837-852.
33. 33. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13:602-614. (Pubitemid 30782013)
34. Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyhty H. Contributions of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999; 118:402-407.
35. Kolibab K, Smithson SL, Shriner AK, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: antibody concentrations, avidity, and functional activity. Immun Aging 2005; 2:10.
36. Tarragó D, Aguilar L, Jansen WTM, et al. Dependence of correlation between antibody titres and opsonphagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states. Clin Microbiol Infect 2007; 13:369-376.
37. 37.WaitesKB,CanuppKC,ChenY,DeVivoMJ,NahmMH. Revaccinationofadultswithspinalcordinjuryusingthe23- valentpneumococcalpolysaccharidevaccine.JSpinalCordMed2008;31:53-59. (Pubitemid351838096)